14, 28, 29 Based on the finding that everolimus Table 1, 11 17 an inhibitor of the mammalian target of rapamycin mTOR, in combination with exemestane is effective in BC patients with endocrine resistance, 30, 31 the US Food and Drug Administration recently approved this combination for treating patients with HR ABC refractory to prior nonsteroidal AI therapy where can i get nolvadex